Literature DB >> 19853373

mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice.

Guiqin Hou1, Qi Zhang, Lili Wang, Mingyue Liu, Jianren Wang, Lexun Xue.   

Abstract

Accumulating evidences have demonstrated that mTOR pathway has a central role not only in cell growth but also in invasion and metastasis of cancers. Here we reported that rapamycin or cisplatin alone inhibited significantly the tumor growth and their combination had the strongest anticancer effect on transplantable tumor growth of human ESCC cell line EC9706 in nude mice. Furthermore, western blots, RT-PCR and TUNEL assay revealed that rapamycin specifically blocked mTOR pathway and induced apoptosis of ESCC cells in vivo. These findings indicate a rationale for using mTOR inhibitors as a mechanism-based therapeutic approach to patients with ESCC. 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853373     DOI: 10.1016/j.canlet.2009.09.015

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  21 in total

1.  Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells.

Authors:  Li Hou; Bo Xu; Wei Guo; Fu-Xiang Ran; Jing-Tao Liu; Xia Yuan; Hong-Zheng Fu; Jing-Rong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2012-05       Impact factor: 4.553

2.  Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.

Authors:  Huaimin Liu; Xin Wang; Guirong Shi; Lifeng Jiang; Xiaoli Liu
Journal:  Tumour Biol       Date:  2014-05-23

3.  High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma.

Authors:  Chi-Ju Yeh; Wen-Yu Chuang; Yin-Kai Chao; Yun-Hen Liu; Yu-Sun Chang; Shao-Yun Kuo; Chen-Kan Tseng; Hsien-Kun Chang; Chuen Hsueh
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

4.  Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication.

Authors:  Xinping Fu; Lihua Tao; Armando Rivera; Xiaoliu Zhang
Journal:  Int J Cancer       Date:  2011-02-26       Impact factor: 7.396

5.  Mutational analysis of the PTEN gene and its effects in esophageal squamous cell carcinoma.

Authors:  Guiqin Hou; Zhaoming Lu; Mingyue Liu; Hongmin Liu; Lexun Xue
Journal:  Dig Dis Sci       Date:  2010-11-30       Impact factor: 3.199

6.  mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.

Authors:  Zhaoming Lu; Yalin Zhang; Yujia Xu; Huiyun Wei; Wen Zhao; Pengju Wang; Yan Li; Guiqin Hou
Journal:  Mol Biol Rep       Date:  2021-11-03       Impact factor: 2.316

7.  Overexpression of S-adenosylhomocysteine hydrolase (SAHH) in esophageal squamous cell carcinoma (ESCC) cell lines: effects on apoptosis, migration and adhesion of cells.

Authors:  Qinghua Li; Lihong Mao; Ruili Wang; Liqiang Zhu; Lexun Xue
Journal:  Mol Biol Rep       Date:  2014-01-16       Impact factor: 2.316

8.  Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κB signaling pathway.

Authors:  Jin Xia; Feng Wang; Liuxing Wang; Qingxia Fan
Journal:  Tumour Biol       Date:  2012-10-19

9.  Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Authors:  Cun Wang; Dongmei Gao; Kun Guo; Xiaonan Kang; Kai Jiang; Chun Sun; Yan Li; Lu Sun; Hong Shu; Guangzhi Jin; Haiyan Sun; Weizhong Wu; Yinkun Liu
Journal:  BMC Cancer       Date:  2012-05-04       Impact factor: 4.430

10.  Inhibiting autophagy enhances sulforaphane-induced apoptosis via targeting NRF2 in esophageal squamous cell carcinoma.

Authors:  Zhaoming Lu; Yandan Ren; Li Yang; Ang Jia; Yi Hu; Yu Zhao; Wuduo Zhao; Bin Yu; Wen Zhao; Jianying Zhang; Guiqin Hou
Journal:  Acta Pharm Sin B       Date:  2020-12-15       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.